A-Clinical-Study-of MK-1084-and-Other-Treatments-for-Participants-With-Non--Small-Cell-Lung-Cancer
A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084 in Combination With Subcutaneous Pembrolizumab and Berahyaluronidase alfa (MK-3475A) Versus MK-3475A in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Chemotherapy as First-line Treatment of Participants With KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC (KANDLELIT-007)
Protocol # MK 1084-007
Contact
clinicaltrials.gov/study/NCT06345729?term=NCT06345729&rank=1
Principal Investigator(s)
Sponsor(s)
Merck Sharp & Dohme LLC
Location
Bennett Cancer Center
One Hospital Plaza
Stamford, CT 06902
Main: 203-358-8879
Stamford, CT 06902
Main: 203-358-8879